Alex Willcockson, PhD (she/her)
LightNews LightNews
banner
awillcockson.bsky.social
Alex Willcockson, PhD (she/her)
@awillcockson.bsky.social
220 followers 820 following 0 posts
Midwesterner by birth, Texan by circumstance. Biologist by training @UTSWNews PhD @wustl BA. Now focused on rare kidney diseases.
Posts Replies Media Videos
Reposted by Alex Willcockson, PhD (she/her)
isgd.bsky.social
Post-ASN, the ISGD team visited Galveston and the UTMB campus and team! We chose the venue for the Inaugural 2026 ISGD Clinical Trials Summit. Please save the date: November 12-16, 2026. Stay tuned for more updates on this landmark event! #ClinicalTrials #ISGD @tobias-b-huber.bsky.social
November 16, 2025 at 7:47 PM
Reposted by Alex Willcockson, PhD (she/her)
hswapnil.medsky.social
The annual @asnkidney.bsky.social Fellows survey is out

data.asn-online.org/posts/2025_f...

Thanks @kpivert.bsky.social et al

#KidneyWk #NephSky
ASN Data
Insights from the 12th Annual ASN Nephrology Fellow Survey
data.asn-online.org
November 6, 2025 at 12:37 PM
Reposted by Alex Willcockson, PhD (she/her)
asnpublications.bsky.social
Immunoglobulin A nephropathy (IgAN) research is evolving fast, but identifying factors that predict progression is high priority. In this month's #ASNKidneyNews, authors review a recent study which examined a diverse patient population with IgAN. Kidney.pub/KN1709-11
September 26, 2025 at 5:00 PM
Reposted by Alex Willcockson, PhD (she/her)
kdigo.org
KDIGO is pleased to announce the publication of the 2025 IgA Nephropathy (#IgAN) and IgA Vasculitis (#IgAV) Guideline, along with its Executive Summary in @kidneyint.bsky.social.

Download: kdigo.co/KDIGO-IgAN-I...

Read in KI: kdigo.co/KDIGO-IgAN-I...

Exec Summary: kdigo.co/IgAN-IgAV-Gu...
September 18, 2025 at 10:34 AM
Reposted by Alex Willcockson, PhD (she/her)
edgarvlermamd.bsky.social
Phase 3 clinical trials open in 2025 evaluating new treatments for IgA Nephropathy #IgAN from @kdigo.org
#Nephpearls #NephSky

👉🏼 kdigo.org/guidelines/i...
September 18, 2025 at 11:52 AM
Reposted by Alex Willcockson, PhD (she/her)
pathologyoutlines.bsky.social
Check out our latest “What’s New in Pathology” newsletter!

June 2025 Issue: "What’s New in Medical Renal Pathology 2025: Updates on Podocytopathy and Immunofluorescence Staining in Medical Kidney" -- Read or download PDF: buff.ly/thzp6rW

#Pathology #PathologyOutlines #RenalPath #PathSky
June 23, 2025 at 6:47 PM
Reposted by Alex Willcockson, PhD (she/her)
nkf-professionals.bsky.social
🧪 Dual angiotensin/endothelin receptor antagonism is making waves in nephrology.

Our new podcast dives into potential impact on #IgAN with insights from recent clinical trials in #FSGS.

Listen in on it!

🎧 bit.ly/3CVPCpw

#Nephrology #KidneyDisease #HealthcareInnovation
May 12, 2025 at 1:05 PM
Reposted by Alex Willcockson, PhD (she/her)
renalpathsociety.bsky.social
Join us for RPS-GlomCon #renalpath webinar lecture on Alport kidney disease spectrum
@glomcon.org
@renalpathsociety.bsky.social
Lecturer: Dr. Jeffrey Milner, PhD, FASN
Sunday, June 22, 2025
To register visit: renalpathsoc.org/event-6113933
#pathsky #nephsky #medsky #alport
June 9, 2025 at 7:46 PM
Reposted by Alex Willcockson, PhD (she/her)
wisit661.bsky.social
🧬 Brilliant and eye-opening talk by Dr. Simone Sanna-Cherchi @SannaCherchiLab on:
“Clinical Features and Genetic Testing in an Inherited Form of Nephrotic Syndrome (NS)” @genetickidneydoc.bsky.social
June 1, 2025 at 10:38 AM
Reposted by Alex Willcockson, PhD (she/her)
theisn.org
𝗧𝗢𝗗𝗔𝗬: ISN-TTS Webinar: Treatment of post-transplant recurrent FSGS in children."

🗣️ Jaime Restrepo, Javier Andrés Tascón Hernández, David Andres Ballesteros Castro
👥 Nancy Rodig, Rupesh Raina
🗓️ May 27
🕑 2:00 pm CEST
🔗 Free registration: http://lite.spr.ly/6...
May 27, 2025 at 6:00 AM
Reposted by Alex Willcockson, PhD (she/her)
ukkidney.org
📢 New @RenalRadar paper!

The study explores how nephrotic syndrome progresses & the link between proteinuria & kidney failure risk.

🔍 Insights will help clinicians identify higher risk patients earlier & improve clinical trial design.

Read more 👉 ow.ly/xVyz50VTPQP
May 21, 2025 at 6:19 PM
Reposted by Alex Willcockson, PhD (she/her)
nkf-professionals.bsky.social
🎧 New podcast out now!

We’re talking breakthroughs in #IgAN & #FSGS, with fresh trial data and insights into dual angiotensin/endothelin receptor antagonism.

Essential listening for #Nephrology pros.

🔗 bit.ly/3CVPCpw

#KidneyHealth #MedicalPodcast #ClinicalResearch
May 20, 2025 at 2:14 PM
Reposted by Alex Willcockson, PhD (she/her)
asnpublications.bsky.social
New Podcast: Dr. Tobias Hermle & Dominik Spitz discuss a proof-of-concept for whole-animal drug screening using podocyte-like Drosophila nephrocytes. Pilot screen using the novel podocytopathy platform identifies that zacopride restores slit diaphragms despite excess of Rac1. https://bit.ly/JPOD0677
A Drug-Screening Platform for Podocytopathies in Drosophila Nephrocytes
May 16, 2025 at 5:00 PM
Reposted by Alex Willcockson, PhD (she/her)
kdigo.org
KDIGO IgAN Infographic: kdigo.co/2024-IgAN-In...
Get a quick overview of key recommendations from the upcoming KDIGO IgAN Guideline with this easy-to-follow infographic.
May 14, 2025 at 5:05 PM
Reposted by Alex Willcockson, PhD (she/her)
isgd.bsky.social
PARASOL biostats leads Abigail Smith and Margaret Helmuth gave a guest lecture today in @mesohaline.bsky.social’s #HamiltonCollege BIO 202 Biostatistics class - Nice examples of statistical methods & considerations in longitudinal studies and clinical trials & real life impact of biostats work
PARASOL project biostatisticians Margaret Helmuth and Abigail Smith, and ISGD director Laurel Damashek, participating via Zoom in a Hamilton College biology classroom
May 8, 2025 at 1:22 AM
Reposted by Alex Willcockson, PhD (she/her)
nkf-professionals.bsky.social
🎧 Exciting breakthroughs in #IgAN and #FSGS are reshaping nephrology!

Tune in to our new podcast as we explore cutting-edge trial results investigating dual angiotensin/endothelin receptor antagonism for kidney care.

🎙️ Listen now: bit.ly/3CVPCpw

#Nephrology #KidneyHealth #MedicalPodcast
May 7, 2025 at 4:04 PM
Reposted by Alex Willcockson, PhD (she/her)
ped-neph.bsky.social
Although female patients w/X-linked Alport syndrome generally have a milder prognosis than males, some female patients show poor prognosis. Read these Clinical Insights into clinical differences between female monozygotic twins w/XLAS w/somatic mosaicism.
link.springer.com/article/10.1...
May 2, 2025 at 5:11 PM
Reposted by Alex Willcockson, PhD (she/her)
jarcyzphd.bsky.social
Hey I know these people! Check out this paper👇
ajkd.bsky.social American Journal of Kidney Diseases @ajkd.bsky.social · Apr 23
Glucocorticoid Exposure and Infection in Children and Adults With Glomerular Disease: Findings From the Cure Glomerulonephropathy Study

bit.ly/3DHbXai (FREE)
April 24, 2025 at 2:28 AM
Reposted by Alex Willcockson, PhD (she/her)
theisn.org
Nephrology Health Professionals’ Perspectives on their Preferred Modality for Scientific Meetings, Balancing Affordability, Sustainability, and Opportunities to Interact with Peers. 2025 from @kireports.bsky.social.

www.kireports.org/ar...
April 24, 2025 at 9:00 AM
Reposted by Alex Willcockson, PhD (she/her)
cuimcglomcenter.bsky.social
Happy Tuesday! Check out “Clinical Decision-Making About Immunosuppressive Treatment in Focal Segmental Glomerulosclerosis” with Dr. Canetta as a coauthor in collaboration with CureGN
pmc.ncbi.nlm.nih.gov...
April 15, 2025 at 10:00 PM
Reposted by Alex Willcockson, PhD (she/her)
edgarvlermamd.bsky.social
Improving Proteinuria With Sparsentan (SPAR) in Patients (Pts) With IgA Nephropathy (IgAN): A Case Series
#Nephpearls #NKFClinicals 🇺🇸 #NephSky

👉 medicalaffairs.travere.com/meetings-eve...
April 15, 2025 at 1:04 AM
Reposted by Alex Willcockson, PhD (she/her)
edgarvlermamd.bsky.social
Sparsentan as First-Line Treatment of Incident Patients with IgAN: Interim Analysis of the SPARTAN Trial
#Nephpearls #NKFClinicals 🇺🇸 #NephSky

📌 The rapid reduction of u-sCD163 levels is the first demonstration of SPAR’s anti-inflammatory effect in humans and supports preclinical data
April 15, 2025 at 1:17 AM
Reposted by Alex Willcockson, PhD (she/her)
edgarvlermamd.bsky.social
PARASOL ☂️: Achieving proteinuria <0.7 g/g is associated with meaningful reduction in kidney failure risk in FSGS
#Nephpearls #NKFClinicals #NephSky
April 11, 2025 at 4:54 AM
Reposted by Alex Willcockson, PhD (she/her)
theisn.org
Findings on the Sparsentan study: A New Dawn for IgA Nephropathy.

⬇️ Download the visual abstract: http://lite.spr.ly/6...
📽️ Watch the industry webinar: http://lite.spr.ly/6...

Supported by @http://lite.spr.ly/6007Gjrh
April 11, 2025 at 10:00 AM
Reposted by Alex Willcockson, PhD (she/her)
nephtimes.bsky.social
⚠️ Late-breaking abstracts will be presented at #NKFClinicals at 2 pm ET. Keep an eye on our coverage of research from this event 👉 buff.ly/66ISbE9 #nephrology #nephsky #kidneydisease
April 10, 2025 at 5:15 PM